Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 8/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497209 | 0.94 | CCR8 (0.75) | CCR8KCNH2SIGMAR1DRD4 | |
| SCHEMBL6497203 | 0.94 | CCR8 (0.75) | CCR8KCNH2SIGMAR1DRD4 | |
| SCHEMBL6501479 | 0.94 | CCR8 (0.75) | CCR8KCNH2SIGMAR1DRD4 | |
| SCHEMBL6497669 | 0.91 | CCR8 (1.00) | CCR8KCNH2SIGMAR1 | |
| SCHEMBL6498271 | 0.89 | CCR8 (0.82) | CCR8SIGMAR1MAOAMAOB | |
| SCHEMBL6505880 | 0.87 | CCR8 (0.67) | CCR8KCNH2MAOBDRD4 | |
| SCHEMBL6508151 | 0.86 | CCR8 (0.89) | CCR8KCNH2SIGMAR1 | |
| SCHEMBL6498389 | 0.86 | CCR8 (0.89) | CCR8KCNH2SIGMAR1DRD4 | |
| SCHEMBL6498379 | 0.86 | CCR8 (0.89) | CCR8KCNH2SIGMAR1DRD4 | |
| SCHEMBL6500503 | 0.85 | CCR8 (0.81) | CCR8KCNH2SIGMAR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885KCNH2 4349/4885SIGMAR1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.